GSK Aktie
| 17,34EUR | -0,37EUR | -2,06% |
WKN DE: A3DMB5 / ISIN: GB00BN7SWP63
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 91,52 |
| Gsk Plc Employee Share Ownership Trust | 4,78 |
| The Vanguard Group, Inc. | 3,44 |
| BlackRock Fund Advisors | 3,05 |
| Dodge & Cox | 2,40 |
| Schroder Investment Management Ltd. | 1,86 |
| Wellington Management Co. LLP | 1,81 |
| Norges Bank Investment Management | 1,79 |
| Dodge & Cox International Stock Fund | 1,61 |
| BlackRock Advisors (UK) Ltd. | 1,58 |
| Legal & General Investment Management Ltd. | 1,53 |
| Vanguard Total International Stock Index Fund | 1,35 |
| Silchester International Investors LLP | 1,19 |
| SSgA Funds Management, Inc. | 1,17 |
| SIX SIS Ltd. | 1,08 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 94 066 | 90 096 | 69 400 | 70 212 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,36 | 0,38 | 0,42 | 0,43 | 0,00 |
Bilanz (in Mio. GBP) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 20 247 | 18 674 | 20 769 | 18 644 | 16 997 |
| Summe Anlagevermögen | 60 184 | 60 429 | 39 377 | 40 361 | 42 466 |
| Summe Aktiva | 80 431 | 79 103 | 60 146 | 59 005 | 59 463 |
Bilanz (in Mio. GBP) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 59 623 | 57 761 | 50 050 | 46 210 | 46 377 |
| Summe Eigenkapital | 20 808 | 21 342 | 10 096 | 12 795 | 13 086 |
| Summe Passiva | 80 431 | 79 103 | 60 146 | 59 005 | 59 463 |
Adresse
| 79 New Oxford Street, WC1A 1DG London | |
| Telefon | +44 (20) 8047-5000 |
| Internet | http://www.gsk.com |
Management
|
Amy Altshul
SVP-Legal, Research & Development |
|
Anita Kidgell
Senior Vice President-Corporate Strategy |
|
Anne C. Beal
Independent Non-Executive Director |
|
Anne-Marie Martin
Senior VP & Global Head-Experimental Medicine Unit |
|
Carlo Russo
Head-Development R&D Biopharm |
|
Charles A. Bancroft
Senior Independent Non-Executive Director |
|
Christopher Corsico
Senior Vice President-Development |
|
Claire Lund
Head-Environmental Sustainability |
|
David Simon Redfern
President-Corporate Development |
|
Diana Conrad
Chief People Officer |
|
Elizabeth McKee Anderson
Independent Non-Executive Director |
|
Emma N. Walmsley
Chief Executive Officer & Executive Director |
|
Frannie DeFranco
Director-Philadelphia Investor Relations |
|
Graham Rivers
Vice President & Financial Controller |
|
Hal V. Barron
Non-Independent Non-Executive Director |
|
Harry C. Dietz
Independent Non-Executive Director |
|
James Ford
Group General Counsel, Head-Legal & Compliance |
|
Jeannie T. Lee
Non-Executive Director |
|
Jesse L. Goodman
Independent Non-Executive Director |
|
Jonathan Richard Symonds
Non-Executive Chairman |
|
Julie Brown
Chief Financial Officer & Executive Director |
|
Luke Miels
Chief Commercial Officer |
|
María Cristina de Luna Basagoiti
General Manager-Spain |
|
Maya Martinez-Davis
President-US Pharmaceuticals |
|
Michael Elmore
Senior Vice President |
|
Mick John Readey
Investor Relations Contact |
|
Philip Thomson
President-Global Affairs |
|
Regis Jean-Pierre Simard
President-Global Supply Chain |
|
Shobie Ramakrishnan
Chief Digital & Technology Officer |
|
Sonya Ghobrial
Head-Consumer Healthcare Investor Relations |
|
Timothy Woodthorpe
Group Treasurer & Senior Vice President |
|
Tony Wood
Chief Scientific Officer |
|
Victoria A. Whyte
Secretary |
|
Vishal Sikka
Independent Non-Executive Director |
|
Wendy Becker
Non-Executive Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.